EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and safety of rabbit ATLG and ATG in allogeneic hematopoietic stem cell transplantation for children with acquired severe aplastic anemia

Senlin Zhang, Qi Ji, Li Gao, Qingwei Wang, Kai Cui, Minyuan Liu, Bohan Li, Yixin Hu, Yongping Zhang, Yuanyuan Tian, Shengqin Cheng, Jun Lu und 1 weitere

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06461-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Senlin Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China. Hauptthemen laut MEDLINE: Anemia, Aplastic, Antilymphocyte Serum, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, Suzhou Projects, The National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe aplastic anemia (SAA) is a life-threatening bone marrow failure syndrome characterized by bone marrow hypoplasia and peripheral blood cytopenia. Without timely treatment, it frequently proves fatal. Rabbit anti-thymocyte globulin (ATG) and anti-human T lymphocyte globulin (ATLG) are widely used for graft-versus-host disease (GVHD) prophylaxis. However, their comparative efficacy in pediatric SAA remains undetermined. This study involved a single-center retrospective analysis of two ATG preparations in pediatric patients undergoing allo-HSCT. The primary endpoint was the incidence of GVHD and viral reactivation following HSCT. Secondary endpoints included overall survival (OS), GVHD-free and failure-free survival (GFFS), neutrophil engraftment, platelet engraftment, hemorrhagic cystitis (HC), tolerability, and toxicities within each group. A total of 124 pediatric SAA patients who underwent their first allo-HSCT between January 2019 and March 2024 were enrolled, with 35 receiving ATLG and 89 receiving ATG. OS, GFFS, GVHD, and HC incidence were comparable between the ATLG and ATG groups (OS: 95.2% vs. 92.9%, P = 0.617). ATLG significantly reduced the incidence of 180-day CMV (45.7% vs. 74.2%, P = 0.0062) and EBV reactivation (29.8% vs. 52.8%, P = 0.025). Additionally, ATLG was associated with fewer adverse events (AEs), including fever (P = 0.009) and rash (P = 0.018). ATLG demonstrated comparable efficacy to ATG in preventing GVHD and achieving OS in pediatric SAA patients undergoing allo-HSCT, while significantly reducing viral reactivation and AEs. These findings support ATLG as a safer alternative, warranting further prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, AplasticAntilymphocyte SerumHematopoietic Stem Cell TransplantationHumansFemaleChildMaleRetrospective StudiesRabbitsGraft vs Host DiseaseChild, PreschoolAdolescentAnimalsInfantTransplantation, HomologousTreatment Outcome

Stichwörter der Autor:innen

Allogeneic hematopoietic stem cell transplantationAnti-thymocyte globulinChildrenSevere aplastic anemia

Substanzen

Antilymphocyte Serum

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China.
  • Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China. drlujun_sz@163.com.
  • Pediatric Hematology and Oncology Center of Jiangsu Province, Children's Hospital of Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China. drlujun_sz@163.com.
  • Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China. hushaoyan@suda.edu.cn.
  • Jiangsu Pediatric Hematology and Oncology Center, No. 92, Zhongnan Street, Suzhou, 215000, China. hushaoyan@suda.edu.cn.
  • Pediatric Hematology and Oncology Center of Jiangsu Province, Children's Hospital of Soochow University, No. 92, Zhongnan Street, Suzhou, 215000, China. hushaoyan@suda.edu.cn.

Förderung

  • the National Natural Science Foundation of China
  • Suzhou Projects
  • The National Key Research and Development Program of China
  • the Suzhou Municipal Key Laboratory
  • Soochow University of Medical School

Zitieren

APA

Zhang, S., Ji, Q., Gao, L., Wang, Q., Cui, K., Liu, M., Li, B., Hu, Y., Zhang, Y., Tian, Y., Cheng, S., Lu, J., & Hu, S. (2025). Efficacy and safety of rabbit ATLG and ATG in allogeneic hematopoietic stem cell transplantation for children with acquired severe aplastic anemia. Annals of Hematology. https://doi.org/10.1007/s00277-025-06461-4

Vancouver

Zhang S, Ji Q, Gao L, Wang Q, Cui K, Liu M, et al. Efficacy and safety of rabbit ATLG and ATG in allogeneic hematopoietic stem cell transplantation for children with acquired severe aplastic anemia. Annals of Hematology. 2025. doi:10.1007/s00277-025-06461-4

BibTeX
@article{Zhang2025,
  author = {Zhang, Senlin and Ji, Qi and Gao, Li and Wang, Qingwei and Cui, Kai and Liu, Minyuan and Li, Bohan and Hu, Yixin and Zhang, Yongping and Tian, Yuanyuan and Cheng, Shengqin and Lu, Jun and Hu, Shaoyan},
  title = {Efficacy and safety of rabbit ATLG and ATG in allogeneic hematopoietic stem cell transplantation for children with acquired severe aplastic anemia},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06461-4}
}
Kostenlos starten →